BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Synexus' Pretoria Clinical Research Site Delivers World Beating Performance for Janssen Pharmaceutical K.K.


10/24/2011 11:39:05 AM

Monday 24th October 2011 -- Synexus’ Pretoria clinical research centre has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

Janssen, a pharmaceutical company of Johnson and Johnson, established more than 99 sites across the globe to enrol the more than 716 patients needed for the study. Synexus, which is the largest multi-national company entirely focused on the recruitment and running of clinical trials at its own Dedicated Research Centres, exceeded its recruitment target by more than 50% at its Watermeyer site in Pretoria.

Synexus country manager Dr. Sanet Aspinall commented “We are often able to exceed our pharma and CRO client’s expectations as we have a very effective enrolment team to recruit patients from the large pool of people surrounding our research centres. This team has developed a sophisticated outreach programme which works closely with GPs, primary care clinics and public hospitals in order to find the right patients quickly.”

Linda Roach, the GCO Country Manager of Janssen Pharmaceuticals in South Africa acknowledged the advantages of working with a dedicated clinical research centre such as the Synexus Watermeyer site: “Within our regulatory environment here in South Africa, we need to partner with sites that can enrol quickly with quality data and can support our efforts to achieve our recruitment targets. Synexus Watermeyer site in Pretoria is one such site.

This is of particularly importance in South Africa as regulatory timelines can be slow leaving a shorter time frame in which to find these patients. Selection of the right site and infrastructure for this study has proven that, the country can not only deliver but exceed the target number of patients.”

This particular study was to enrol patients with type 2 diabetes who are inadequately controlled on glucose lowering therapy.

Synexus, headquartered in Manchester, England, is the world’s largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients. Synexus now has 26 Dedicated Research Centres across the UK, Germany, Austria, Poland, Hungary, Ukraine, Bulgaria, India and South Africa staffed by full-time GCP-trained investigators.

The traditional way of recruiting for clinical trials through individual doctors is still by far the most common method, despite the fact that each doctor only recruits an average of five patients per study and more than 60 percent recruit one or less. This incredibly costly model remains the norm.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES